At a Glance
MedPlus Health, the second largest pharmacy chain in India, just dropped its Q1 FY26 results, and the numbers scream “steady but pricey.” Sales stood at ₹1,543 Cr (up 3.6% QoQ), PAT came in at ₹42 Cr, and EPS was ₹3.54. Meanwhile, the market is pricing the stock at a nosebleed-inducing P/E of 61.5. Promoters hold just 40.3%, with 59% of their stake pledged—because nothing says confidence like pledging more than half your shares. Oh, and Karnataka suspended one of their subsidiary’s drug licenses—revenue impact? A laughable ₹0.18 lakh.
1. Introduction
Picture this: you walk into a MedPlus store, buy a paracetamol, and indirectly contribute to a P/E higher than the temperature in Chennai summers. MedPlus Health has been on an expansion spree, adding 108 net stores in Q2 FY25 and quietly swallowing tier-2 and tier-3 markets. They’ve built an integrated pharmacy model mixing retail stores, e-commerce, private labels, and diagnostics—basically, a pharmacy with a side hustle in everything.
Investors love the growth story, but the valuation? It’s like paying ₹500 for a vitamin C tablet—possible, but painful.
2. Business Model (WTF Do They Even Do?)
MedPlus is a hybrid beast—part retail pharmacy, part FMCG seller, part diagnostics player, and part e-commerce operator. Their 4,552 stores stretch across 12 states, from metro hubs to tiny towns where the only competition is
